An interventional study of MynxGrip and Manual compression in Endovascular, sponsored by Cordis US Corp.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Cordis US Corp. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the safety and effectiveness of MynxGrip, in hemostasis of common femoral artery puncture site, compared with manual compression hemostasis in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
Effectiveness: to superiority to the control group in time to hemostasis. Comparison of time to ambulation, procedure success rate, length of stay in hospital, device success rate.
Safety-Major/Minor complication rate, adverse events, SAEs as compared to control.
Cordis US Corp. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients are proved to have peripheral vascular disease according to any of the following situations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MynxGrip, a vascular closure device indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
Device: MynxGrip
Manual compression hemostasis
Other: Manual compression
Vascular Closure
Manual compression is a commonly used method to achieve hemostasis of femoral artery
Primary Effectiveness Endpoint: Time to Hemostasis
The time to hemostasis is defined as the time from the sheath removal to the time to achieving hemostasis for the subject. The "hemostasis" here refers to that at the puncture site, there is no pulsating bleeding, nor expansionary/progressive hematoma.
Time frame: Post procedure (time from the sheath removal to the time to achieving hemostasis)
Primary Safety Endpoint: Major Complication Rate
Defined as major complications during procedure, at discharge, and 30 days post procedure: vascular injury or vascular repair required; Permanent access site-related nerve injury; Access site-related nerve injury requiring a surgery; Access site-related bleeding requiring transfusion; New ipsilateral lower extremity ischemia discovered, which requires invasive/noninvasive intervention; Local access site-related infection combined with other indicators, which requires intervention; Classic signs/symptoms occurred in a short time after receiving the specified hemostasis procedures and generalized infection with positive blood culture, sepsis, which requiring intervention; Inflammatory reaction, including the local reaction and discharge of pus, which requires intervention
Time frame: Through 30 days post procedure
Secondary Effectiveness Endpoint: Time to Ambulation
Defined as the time (in minutes) from sheath removal to when the patient can walk about at least 6 meters (or 20 steps). Compare whether there are differences in the time to ambulation (for patients receiving a diagnostic procedure) between the two groups.
Time frame: Post procedure
Secondary Effectiveness Endpoint: Length of Hospital Stay
Defined as the time (in minutes) from sheath removal to patient discharge (for patients receiving a diagnostic procedure). Compare whether there are differences in the length of stay (for patients receiving a diagnostic procedure) between the two groups.
Time frame: Index procedure through discharge
Secondary Effectiveness Endpoint: Procedure Success Rate
Defined as successfully achieving hemostasis using the investigational medical device or control methods (including but are not limited to the assigned therapeutic method and other supplementary means) with absence of major complications. Compare whether there are differences in the procedure success rate (for patients receiving a diagnostic procedure) between the two groups.
Time frame: Index procedure
Secondary Effectiveness Endpoint: Device Success Rate
Defined as the device being successfully removed in accordance with the standard operating procedure
Time frame: Intraoperatively
Secondary Safety Endpoint: Minor Complication Rate
Compare whether there are differences in rates of minor complications between the two groups
Time frame: Through 30 days post procedure
Study enrollment began with first patient on 24-Apr-2019 and ended with last patient on 21-Sep-2020.
| Milestone | MynxGrip | Manual Compression |
|---|---|---|
| Started | 204 | 102 |
| Completed | 187 | 92 |
| Not completed | 17 | 10 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Lost to follow-up | 14 | 8 |
| Withdrew: Physician decision | 1 | 0 |
The time to hemostasis is defined as the time from the sheath removal to the time to achieving hemostasis for the subject. The "hemostasis" here refers to that at the puncture site, there is no pulsating bleeding, nor expansionary/progressive hematoma.
| Min | MynxGrip | Manual Compression |
|---|---|---|
| Primary Effectiveness Endpoint: Time to Hemostasis | 4.8 ± 12.10 | 19.8 ± 25.37 |
Defined as major complications during procedure, at discharge, and 30 days post procedure: vascular injury or vascular repair required; Permanent access site-related nerve injury; Access site-related nerve injury requiring a surgery; Access site-related bleeding requiring transfusion; New ipsilateral lower extremity ischemia discovered, which requires invasive/noninvasive intervention; Local access site-related infection combined with other indicators, which requires intervention; Classic signs/symptoms occurred in a short time after receiving the specified hemostasis procedures and generalized infection with positive blood culture, sepsis, which requiring intervention; Inflammatory reaction, including the local reaction and discharge of pus, which requires intervention
| percentage of participants | MynxGrip | Manual Compression |
|---|---|---|
| Primary Safety Endpoint: Major Complication Rate | 0 | 0 |
Defined as the time (in minutes) from sheath removal to when the patient can walk about at least 6 meters (or 20 steps). Compare whether there are differences in the time to ambulation (for patients receiving a diagnostic procedure) between the two groups.
| Min | MynxGrip | Manual Compression |
|---|---|---|
| Secondary Effectiveness Endpoint: Time to Ambulation | 657.0 ± 641.64 | 1306.3 ± 269.84 |
Defined as the time (in minutes) from sheath removal to patient discharge (for patients receiving a diagnostic procedure). Compare whether there are differences in the length of stay (for patients receiving a diagnostic procedure) between the two groups.
| Min | MynxGrip | Manual Compression |
|---|---|---|
| Secondary Effectiveness Endpoint: Length of Hospital Stay | 3104.9 ± 2356.68 | 2721.1 ± 1676.36 |
Defined as successfully achieving hemostasis using the investigational medical device or control methods (including but are not limited to the assigned therapeutic method and other supplementary means) with absence of major complications. Compare whether there are differences in the procedure success rate (for patients receiving a diagnostic procedure) between the two groups.
| Participants | MynxGrip | Manual Compression |
|---|---|---|
| Secondary Effectiveness Endpoint: Procedure Success Rate | 202 | 101 |
Defined as the device being successfully removed in accordance with the standard operating procedure
| Participants | MynxGrip |
|---|---|
| Secondary Effectiveness Endpoint: Device Success Rate | 194 |
Compare whether there are differences in rates of minor complications between the two groups
| percentage of participants | MynxGrip | Manual Compression |
|---|---|---|
| Secondary Safety Endpoint: Minor Complication Rate | 3 | 1 |
Collected over 30 days follow-up. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MynxGrip | 0/204 (0%) | 10/204 (4.9%) | 65/204 (31.9%) |
| Manual Compression | 0/101 (0%) | 2/101 (2%) | 20/101 (19.8%) |
| Event | MynxGrip | Manual Compression |
|---|---|---|
| Left Intracranial HemorrhageNervous system disorders | 0/204 | 1/101 |
| CholecystitisHepatobiliary disorders | 0/204 | 1/101 |
| Retroperitoneal HematomaGastrointestinal disorders | 1/204 | 0/101 |
| Heart DiseaseCardiac disorders | 1/204 | 0/101 |
| Lung CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/204 | 0/101 |
| Splenic InfarctionBlood and lymphatic system disorders | 1/204 | 0/101 |
| AneurysmNervous system disorders | 1/204 | 0/101 |
| Moyamoya DiseaseNervous system disorders | 1/204 | 0/101 |
| Nasopharyngeal FibroangiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/204 | 0/101 |
| Renal Artery Dissection AneurysmRenal and urinary disorders | 1/204 | 0/101 |
| Event | MynxGrip | Manual Compression |
|---|---|---|
| Induration at the puncture siteGeneral disorders | 9/204 | 0/101 |
| VomitGastrointestinal disorders | 5/204 | 3/101 |
| Swelling at puncture siteGeneral disorders | 5/204 | 0/101 |
| NauseaGastrointestinal disorders | 5/204 | 1/101 |
| Hematoma at vascular puncture siteGeneral disorders | 3/204 | 2/101 |
| FeverGeneral disorders | 1/204 | 2/101 |
| Stomach AcheGastrointestinal disorders | 3/204 | 2/101 |
| Upper Abdominal PainGastrointestinal disorders | 0/204 | 2/101 |
| Presence of HematuriaRenal and urinary disorders | 4/204 | 1/101 |
| Increased Blood PressureGeneral disorders | 3/204 | 1/101 |
One subject in the test group and one in the control group were excluded from the full analysis set (FAS) and the per-protocol population set (PPS). One subject in the test group was re-enrolled because it met the exclusion criteria 21, and one in the control group withdrew informed consent before receiving the trial treatment after randomization. In the end, the FAS included 304 subjects, including 203 subjects in the test group and 101 subjects in the control group.
| Age, Continuous(Years) | MynxGrip | Manual Compression | Total |
|---|---|---|---|
| Mean | 59.8 ± 10.83 | 59.7 ± 10.60 | 59.8 ± 10.74 |
| Sex: Female, Male(Participants) | MynxGrip | Manual Compression | Total |
|---|---|---|---|
| Female | 130 | 69 | 199 |
| Male | 73 | 32 | 105 |
| Race/Ethnicity, Customized(Participants) | MynxGrip | Manual Compression | Total |
|---|---|---|---|
| Han | 191 | 97 | 288 |
| Other | 12 | 4 | 16 |
| Height(m) | MynxGrip | Manual Compression | Total |
|---|---|---|---|
| Mean | 1.661 ± 0.0803 | 1.661 ± 0.0741 | 1.661 ± 0.0781 |
| Weight(Kg) | MynxGrip | Manual Compression | Total |
|---|---|---|---|
| Mean | 69.09 ± 10.669 | 70.14 ± 10.383 | 69.44 ± 10.569 |
| BMI(Kg/m^2) | MynxGrip | Manual Compression | Total |
|---|---|---|---|
| Mean | 24.98 ± 2.950 | 25.38 ± 3.092 | 25.12 ± 2.998 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Oct 2020, 17 months.
Results were first posted in Jul 2026, 5 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.